poisar

Stocks · News reference

Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program

Benzinga Newsdesk

Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VSTM
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

    Verastem (VSTM) shares have surged 121% over three months, driven by accelerating sales of ovarian cancer drug Avmapki Fakzynja Co-Pack, which generated $25.1 million in Q2 2026 revenues (up 1,095% YoY), and growing optimism around VS-7375, a KRAS G12D inhibitor in phase II trials across pancreatic, lung, and colorectal cancers. The company expects VS-7375 data in October 2026 and plans FDA meetings before year-end to discuss phase III pivotal trial designs.

    VSTMPGENACIUALDX